Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × INDUSTRY × Selective Serotonin Reuptake Inhibitors × Clear all

Status

Sponsor Class

INDUSTRY 1 FED 1

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 1 Depressive Disorder 1

Interventions

Paclitaxel 423 Carboplatin 373 Gemcitabine 345 Docetaxel 340 Cisplatin 311 Bevacizumab 299 pembrolizumab 283 Nivolumab 221 Pemetrexed 206 Capecitabine 200 Fluorouracil 181 Rituximab 177 Dexamethasone 177 Trastuzumab 167 Cyclophosphamide 163 Oxaliplatin 144 Erlotinib Hydrochloride 131 Prednisone 130 atezolizumab 128 Ipilimumab 125 Cetuximab 123 Irinotecan 122 Leucovorin 116 Doxorubicin 116 Bortezomib 105 Sorafenib 101 Sunitinib 95 Lenalidomide 95 Radiotherapy 82 Everolimus 82

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01077596 2017-05-30

Carcinogenicity Study of Bupropion

GlaxoSmithKline

50,430 enrolled 23 charts

Depressive Disorder, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡